Qendri V - Search Results

1

Who Will Benefit From Expanding HPV Vaccination Programs to Boys?

Qendri V, Bogaards JA, Berkhof J. Qendri V, et al. JNCI Cancer Spectr. 2018 Dec 21;2(4):pky076. doi: 10.1093/jncics/pky076. eCollection 2018 Oct. JNCI Cancer Spectr. 2018. PMID: 31360888 Free PMC article.

2

Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention.

Qendri V, Schurink-Van 't Klooster TM, Bogaards JA, Berkhof J. Qendri V, et al. Expert Rev Vaccines. 2018 Dec;17(12):1093-1104. doi: 10.1080/14760584.2018.1547196. Epub 2018 Nov 29. Expert Rev Vaccines. 2018. PMID: 30417704 Review.

3

Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands.

Qendri V, Bogaards JA, Berkhof J. Qendri V, et al. J Infect Dis. 2017 Jul 15;216(2):210-219. doi: 10.1093/infdis/jix272. J Infect Dis. 2017. PMID: 28586466

4

The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment.

Qendri V, Bogaards JA, Baussano I, Lazzarato F, Vänskä S, Berkhof J. Qendri V, et al. Lancet Public Health. 2020 Nov;5(11):e592-e603. doi: 10.1016/S2468-2667(20)30209-7. Lancet Public Health. 2020. PMID: 33120045 Free article.

5

Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing.

McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA. McDonald SA, et al. Among authors: qendri v. Cancer Causes Control. 2017 Mar;28(3):203-214. doi: 10.1007/s10552-017-0870-6. Epub 2017 Feb 17. Cancer Causes Control. 2017. PMID: 28213874

6

Pricing of HPV vaccines in European tender-based settings.

Qendri V, Bogaards JA, Berkhof J. Qendri V, et al. Eur J Health Econ. 2019 Mar;20(2):271-280. doi: 10.1007/s10198-018-0996-9. Epub 2018 Jul 26. Eur J Health Econ. 2019. PMID: 30051152 Free PMC article.

7

Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland.

Deb A, Guggisberg P, Mutschler T, Owusu-Edusei K, Bencina G, Johnson KD, Ignacio T, Mathijssen DAR, Qendri V. Deb A, et al. Among authors: qendri v. Expert Rev Vaccines. 2022 May;21(5):711-722. doi: 10.1080/14760584.2022.2046468. Epub 2022 Mar 20. Expert Rev Vaccines. 2022. PMID: 35220875

8

Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.

Wolff HB, Qendri V, Kunst N, Alarid-Escudero F, Coupé VMH. Wolff HB, et al. Among authors: qendri v. Med Decis Making. 2022 Oct;42(7):956-968. doi: 10.1177/0272989X221100112. Epub 2022 May 19. Med Decis Making. 2022. PMID: 35587181 Free PMC article.

9

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.

Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, van de Wetering G, Davids MS. Chatterjee A, et al. Among authors: qendri v. J Manag Care Spec Pharm. 2021 Nov;27(11):1532-1544. doi: 10.18553/jmcp.2021.27.11.1532. J Manag Care Spec Pharm. 2021. PMID: 34714110 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page